Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: Results from the BONE study

Osteoporosis International

Volumn 15, Issue 3, 2004, Pages 231-237

  Recker, R R ^a   Weinstein, R S ^b   Chesnut III, C H ^c   Schimmer, R C ^e   Mahoney, P ^d   Hughes, C ^c   Bonvoisin, B ^f   Meunier, P J ^f  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e ROCHE PRODUCTS LTD   (United Kingdom)

^f EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Histomorphometry; Ibandronate Postmenopausal osteoporosis

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; IBANDRONIC ACID; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; BONE; BONE BIOPSY; BONE DEFECT; BONE DENSITY; BONE MATRIX; BONE MICROARCHITECTURE; BONE MINERALIZATION; BONE MINERALIZATION DEFECT; BONE TURNOVER; BONE VOLUME; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; EXTENDED BETWEEN DOSE INTERVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MORPHOMETRICS; MYELOFIBROSIS; ORGAN SIZE; OSTEOID; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TRABECULAR BONE; ULTRASTRUCTURE; VERTEBRA FRACTURE;

AGED; BIOPSY; BONE REMODELING; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; ILIUM; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS;

EID: 1642371153     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00198-003-1530-0     Document Type: Article

References (15)

1. Frost HM (1969) Tetracycline based histological analysis of bone remodelling. Calcif Tissue Res 3:211-237
2. Delmas P, Recker R, Stakkestad JA, et al (2002) Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: results from a pivotal phase III study (abstract). Osteoporos Int 13 [Suppl 1]:S15
3. Chavassieux PM, Arlot M, Meunier PJ (2001) Clinical use of bone biopsy. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, San Diego, pp 501-509
4. Parfitt AM, Drezner MK, Glorieux FH, et al (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
5. Chavassieux PM, Arlot ME, Reda C, et al (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480
6. Compston JE, Vedi S, Stellon AJ (1986) Inter-observer and intra-observer variation in bone histomorphometry. Calcif Tissue Int 38:67-70
7. Chavassieux PM, Arlot ME, Meunier PJ (1985) Intersample variation in bone histomorphometry: comparison between parameter values measured on two contiguous transiliac bone biopsies. Calcif Tissue Int 37:345-350
8. de Vernejoul MC, Kuntz D, Miravet L, Goutallier D, Ryckewaert A (1981) Bone histomorphometric reproducibility in normal patients. Calcif Tissue Int 33:369-374
9. Bergot C, Laval-Jeantet AM, Laval-Jeantet M (1978) Etude critique des variations de la mesure de la masse osseuse par biopsie iliaque. Rev Rhum Mal Osteoartic 45:317-324
10. Bravenboer N, Papapoulos SE, Holzmann P, Hamdy NA, Netelenbos JC, Lips P (1999) Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteoporos Int 9:489-493
11. Eriksen EF, Melson F, Sod E, Chines A, Law L (2001) The effect of 5-year risedronate therapy on bone histology and histomorphometry (abstract). J Bone Miner Res 16 [Suppl 1]:S218
12. Reid IR, Brown JP, Burckhardt P, et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661
13. Marcus R, Majumdar S (2001) The nature of osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, San Diego, pp 3-17
14. Monier-Faugere MC, Geng Z, Paschalais E, et al (1999) Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 14:1768-1778
15. Smith SY, Recker RR, Hannan M, Müller R, Bauss F (2003) Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32:45-55